Document is current
Any future updates will be listed below
-
Authors
Kamiya, Hideki https://orcid.org/0000-0003-3197-2542
Himeno, Tatsuhito
Watarai, Atsuko
Baba, Masayuki
Nishimura, Rimei
Tajima, Naoko
Nakamura, Jiro
-
Funding
Funding for this research was provided by:
Japan Diabetes Society
- License Information
-
More Information
Article History
Received: 29 June 2023
Accepted: 28 November 2023
First Online: 12 January 2024
Declarations
:
: Hideki Kamiya: Lecture fees: Novo Nordisk Pharma, Sanofi, Sumitomo Pharma, Nippon Boehringer Ingelheim, Eli Lilly Japan, Daiichi Sankyo, Ono Pharmaceutical, Kissei Pharmaceutical, Mitsubishi Tanabe Pharma, Kowa, Novartis Pharma, MSD, Sanwa Kagaku Kenkyusho. Research funding: Eli Lilly Japan, Ono Pharmaceutical, Kissei Pharmaceutical. Subsidies or Donations: MSD, Ono Pharmaceutical, Sumitomo Pharma, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Japan Tobacco, Novo Nordisk Pharma, Taisho Pharmaceutical. Endowed departments by commercial entities: Ono Pharmaceutical, Abbott Japan, Sanwa Kagaku Kenkyusho, Kowa, Terumo. Tatsuhito Himeno: This author reports no conflict of interest. Atsuko Watarai: This author reports no conflict of interest. Masayuki Baba: This author reports no conflict of interest. Rimei Nishimura: Lecture fees: Sanofi, Medtronic Japan, Nippon Behringer Ingelheim, Takeda Pharmaceutical, Kissei, Eli Lilly Japan, Novo Nordisk Pharma, MSD, Astellas Pharma, Abbott Japan. Research funding: Japan Diabetes Foundation. Subsidies or Donations: Taisho Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceutical, Nippon Boehringer Ingelheim, Sumitomo Pharma, Abbott Japan. Naoko Tajima: This author reports no conflict of interest. Jiro Nakamura: Lecture fees: MSD, Novo Nordisk Pharma, Sanofi, Daiichi Sankyo, Ono Pharmaceutical, Novartis Pharma, Taisho Pharmaceutical, Takeda Pharmaceutical, Terumo. Research funding: Eli Lilly Japan, Ono Pharmaceutical, Kissei Pharmaceutical. Subsidies or Donations: MSD, Ono Pharmaceutical, Sumitomo, Pharma, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Japan Tobacco, Novo Nordisk Pharma, Taisho Pharmaceutical. Endowed departments by commercial entities: Ono Pharmaceutical, Abbott Japan, Sanwa Kagaku Kenkyusho, Kowa, Terumo.
: Approval of the research protocol: The JDCP study was approved by the Japan Diabetes Society Ethics Review Committee for Scientific Surveys and Studies, and by the ethics committee and institutional review board of each site (approved on July 2, 2013, approval number: not applicable). Approval date of Registry and the Registration No. of the study/trial: 4/6/2007, UMIN000016519.
: Not applicable.
: Not applicable.
